New drug combo shows promise in early cancer trial
NCT ID NCT03396445
First seen Nov 05, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-stage study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy Keytruda, in 182 adults with advanced solid tumors, including lung and triple-negative breast cancers. The main goals were to check safety and how the drug moves through the body. Researchers also looked at adding chemotherapy to the mix. The trial has completed, but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Antoni van Leeuwenhoek Ziekenhuis ( Site 0003)
Amsterdam, North Holland, 1066 CX, Netherlands
-
Bradfordhill-Clinical Area ( Site 0501)
Santiago, Region M. de Santiago, 8420383, Chile
-
Centro Integral Oncologico Clara Campal START Madrid ( Site 0040)
Madrid, 28050, Spain
-
Erasmus MC ( Site 0031)
Rotterdam, South Holland, 3015 GD, Netherlands
-
FALP-UIDO ( Site 0502)
Santiago, Region M. de Santiago, 6900941, Chile
-
Florida Cancer Specialists ( Site 0002)
Sarasota, Florida, 34232, United States
-
Hadassah Ein Kerem Medical Center ( Site 0010)
Jerusalem, 9112001, Israel
-
Hospital Universitario Fundacion Jimenez Diaz ( Site 0041)
Madrid, 28040, Spain
-
Hospital Universitario Quiron Madrid ( Site 0043)
Pozuelo de Alarcón, Madrid, 28223, Spain
-
Instituto Catalan de Oncologia - ICO ( Site 0044)
Barcelona, 08916, Spain
-
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0802)
Taipei, 112, Taiwan
-
National Taiwan University Hospital-Oncology ( Site 0801)
Taipei, 100, Taiwan
-
Seoul National University Hospital-Internal Medicine ( Site 0702)
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0701)
Seoul, 03722, South Korea
-
Soroka Medical Center-Oncology ( Site 0012)
Beersheba, 8400000, Israel
-
The Chaim Sheba Medical Center - Oncology Institute ( Site 0001)
Ramat Gan, 5265601, Israel
-
The West Clinic, P.C. ( Site 0021)
Germantown, Tennessee, 38138, United States
-
University of South Alabama, Mitchell Cancer Institute ( Site 0020)
Mobile, Alabama, 36604, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Boserolimab (MK-5890) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could lead to a new combination treatment option for advanced solid tumors like lung and breast cancer.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.